pete_nash — that is really helpful context on Retatrutide and fatty. Follow-up question: what labs did your doctor order to monitor this?
I am in a similar situation (just started) and trying to set realistic expectations.
To answer BenResearch_OR's question specifically:
From a clinical standpoint, Retatrutide and fatty liver is an area where we have good evidence.
The short answer: baseline labs + quarterly monitoring is the standard of care.
The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.
Thank you MaxMetOK! This is incredibly helpful. Bookmarking for later. 🙏
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsRelevant to Retatrutide and fatty liver — here is my latest bloodwork comparison:
Key improvements: A1C 8.4% → 5.5%, triglycerides 209 → 109 mg/dL, hsCRP 8.0 → 0.9 mg/L. All on tirzepatide for 13 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
Slightly tangential to Retatrutide and fatty but MaxMetOK reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.